The post Bitcoin Turns Volatile After Reports of US Airstrikes in Venezuela appeared on BitcoinEthereumNews.com. Early on Jan. 3, reports said the United StatesThe post Bitcoin Turns Volatile After Reports of US Airstrikes in Venezuela appeared on BitcoinEthereumNews.com. Early on Jan. 3, reports said the United States

Bitcoin Turns Volatile After Reports of US Airstrikes in Venezuela

Early on Jan. 3, reports said the United States carried out airstrikes inside Venezuela, with explosions reported in Caracas and nearby states. Venezuelan authorities accused Washington of hitting military-linked targets and announced emergency security measures after the blasts.

U.S. President Donald Trump later said Nicolás Maduro and his wife, Cilia Flores, were captured and flown out of the country following the operation. At the time of reporting, officials did not publish a detailed briefing that confirmed targets, timing, or the claim’s operational details.

Source: TruthSocial/@realDonaldTrump

Airspace warnings and flight restrictions also surfaced in early coverage. As a result, traders treated the headlines as an immediate macro risk event, even while many facts remained unsettled.

Bolivar Weakness and Dollar Pricing Fueled USDT Demand

Venezuela entered the latest shock with a fragile currency setup. The Venezuelan bolívar has faced repeated depreciation pressure, while many merchants price goods in U.S. dollars to avoid fast-changing local costs.

 USD/VES Exchange Rate Trend. Source: Trading Economics

That gap creates a daily conversion problem. People often earn or hold bolívars, yet they need dollars for rent, imports, and bigger purchases, so exchange rates matter even for routine spending.

In that environment, USDT has expanded as a “digital dollar” substitute for transfers and short-term savings. When cash USD gets scarce or risky to move, USDT can act as a bridge between bolívars and dollar-based pricing, including for business payments.

Bitcoin Price Mirrors Israel–Iran Headline Volatility

Bitcoin traded in a wide intraday range on Jan. 3, and the chart shows sharp swings instead of a one-way move. Price fell toward $88,600 in the late afternoon, then it rebounded fast and pushed above $90,500 in the evening. After that spike, Bitcoin drifted lower in choppy trading, and it later dipped again near $89,400 before stabilizing around $89,700.

Bitcoin (BTC) Intraday Price Chart (Jan. 3). Source: CoinCodex

The price action fits a risk-off, headline-driven tape because the moves came in quick bursts and then faded into sideways trade. However, this chart alone cannot confirm why the swings happened, and it also does not show stablecoin flows or derivatives positioning. It only shows spot price movement across the session.

During the opening phase of the Israel–Iran escalation, Bitcoin also swung sharply, with fast drops followed by quick rebounds. That kind of two-way tape often signals that traders react to headlines first, then reset positions as more information arrives. 

Source: https://coinpaper.com/13512/bitcoin-reacts-to-venezuela-airstrike-reports-as-geopolitical-risk-surges

Market Opportunity
Talus Logo
Talus Price(US)
$0.00628
$0.00628$0.00628
-0.63%
USD
Talus (US) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26